FORA Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

FORA Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,997	Closed	-$1.16M	–	535
2025 Q4	$1.16M	Sell	1,997 -506	-20%	-$258K	0.14%	184
2025 Q3	$1.15M	Buy	+2,503	New	+$934K	0.2%	139
2025 Q1	–	Sell	-1,123	Closed	-$347K	–	593
2024 Q4	$347K	Buy	+1,123	New	+$316K	0.04%	301
2023 Q1	–	Sell	-4,851	Closed	-$1.41M	–	627
2022 Q4	$1.41M	Buy	+4,851	New	+$474K	0.23%	121
2021 Q3	–	Sell	-543	Closed	-$53K	–	658
2021 Q2	$53K	Buy	+543	New	+$64.3K	0.01%	704
2021 Q1	–	Sell	-1,026	Closed	-$114K	–	964
2020 Q4	$114K	Buy	+1,026	New	+$125K	0.02%	636
2020 Q3	–	Sell	-1,282	Closed	-$145K	–	853
2020 Q2	$145K	Buy	+1,282	New	+$126K	0.05%	413

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FORA Capital's MDGL Position: Q1 2026 in Review

FORA Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 1,997 shares — an estimated $1.16M sold.

FORA Capital first reported a position in MDGL in Q2 2020 and held it in 7 quarters. The position peaked at $1.41M in Q4 2022. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

FORA Capital reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
FORA Capital sold 1,997 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.16M.
FORA Capital first reported a position in Madrigal Pharmaceuticals in Q2 2020 and held it in 7 quarters.
FORA Capital's Madrigal Pharmaceuticals position peaked at $1.41M in Q4 2022.
380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.